SCHEMBL10065844

SCHEMBL10065844

CN[C@H](Cc1cccc(F)c1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 2/20 0.56
CTSS P25774 1/20 0.49
CTSK P43235 1/20 0.49
PPARG P37231 5/20 0.49
PPARA Q07869 3/20 0.49
GPR34 Q9UPC5 2/20 0.46
TAAR1 Q96RJ0 1/20 0.46
FOLH1 Q04609 1/20 0.45
SRC P12931 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29696653 1.00 SLC1A1 (0.56) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL8986524 1.00 SLC1A1 (0.56) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL31754259 1.00 SLC1A1 (0.56) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL8986521 1.00 SLC1A1 (0.56) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL9463694 0.97 SLC1A1 (0.54) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL24711924 0.88 SLC1A1 (0.49) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL14942947 0.88 SLC1A1 (0.49) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL12668877 0.88 SLC1A1 (0.49) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL22290967 0.86 SLC1A1 (0.57) SLC1A1CTSSCTSKPPARGPPARA
SCHEMBL30118360 0.85 MME (0.50) CTSSCTSKGPR34ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US claimed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
US-20120071329-A1 METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES GLAXOSMITHKLINE LLC (US) 2012-03-22 US disclosed
US-20110251089-A1 METHODS FOR SYNTHESIS OF ENCODED LIBRARIES GLAXOSMITHKLINE (US) 2011-10-13 US disclosed
US-7989395-B2 Methods for identifying compounds of interest using encoded libraries GLAXOSMITHKLINE LLC (US) 2011-08-02 US disclosed
US-7935658-B2 Methods for synthesis of encoded libraries PRAECIS PHARMACEUTICALS, INC. (US) 2011-05-03 US disclosed
US-20090062147-A1 Methods for synthesis of encoded libraries PRAECIS PHARMACEUTICALS INCORPORATED (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251089-A1 METHODS FOR SYNTHESIS OF ENCODED LIBRARIES RNGTT, DTYMK, DUT SLC1A1 2652/4885CTSS 2488/4885CTSK 2110/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 SLC1A1 305/4885CTSS 4675/4885CTSK 4419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.